Quick Takeaways
- ORBIMED ADVISORS LLC filed SCHEDULE 13G/A for C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share (CCCC).
- Disclosed ownership: 1%.
- Date of event: 31 Dec 2025.
ORBIMED ADVISORS LLC - 31 Dec 2025 SCHEDULE 13G/A Report for C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share (CCCC)
- Filing Manager
- ORBIMED ADVISORS LLC
- Reporting Manager
- OrbiMed Capital LLC
- Symbol
- CCCC
- Shares outstanding
- 88,353,400 shares
- Disclosed Ownership
- 883,534 shares
- Ownership
- 1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 18:18:34 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIMED ADVISORS LLC disclosed 1% ownership in C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share (CCCC) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Nov 2025.
- Current filing was accepted on 17 Feb 2026, 18:18.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 0.5% | 521,368 | 0 | 521,368 | /s/ Carl L. Gordon | Carl L. Gordon/Member | |
| OrbiMed Capital LLC | 1% | 883,534 | 883,534 | 0 | /s/ Carl L. Gordon | Carl L. Gordon/Member |